US006054427A

United States Patent [19]

Winslow

[11] **Patent Number: 6,054,427**

[45] **Date of Patent: *Apr. 25, 2000**

[54] **METHODS AND COMPOSITIONS FOR OPTIMIZATION OF OXYGEN TRANSPORT BY CELL-FREE SYSTEMS**

[75] Inventor: **Robert M. Winslow**, La Jolla, Calif.

[73] Assignee: **The Regents of the University of California**, Calif.

[*] Notice: This patent is subject to a terminal disclaimer.

[21] Appl. No.: **09/032,342**

[22] Filed: **Feb. 27, 1998**

Related U.S. Application Data

[63] Continuation-in-part of application No. 08/810,694, Feb. 28, 1997, Pat. No. 5,814,601.

[51] **Int. Cl.**[7] **A61K 38/16**; A61K 35/14

[52] **U.S. Cl.** **514/6**; 514/21; 514/832; 514/833; 530/385; 530/402; 530/813; 530/815; 530/829; 424/529

[58] **Field of Search** 514/6, 21, 832, 514/833; 530/385, 402, 813, 815, 829; 424/529

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,925,344	12/1975	Mazur	260/112.5
3,956,259	5/1976	Garcia et al.	260/112 B
4,001,200	1/1977	Bonsen et al.	260/112.5 R
4,001,401	1/1977	Bonsen et al.	424/177
4,053,590	10/1977	Bonsen et al.	424/177
4,061,736	12/1977	Morris et al.	424/177
4,133,874	1/1979	Miller et al.	424/38
4,179,337	12/1979	Davis et al.	435/181
4,301,144	11/1981	Iwashita et al.	424/78
4,316,093	2/1982	Broers et al.	250/492.1
4,336,248	6/1982	Bonhard et al.	424/101
4,377,512	3/1983	Ajisaka et al.	260/112 B
4,401,652	8/1983	Simmonds et al.	424/101
4,412,989	11/1983	Iwashita et al.	424/177
4,439,357	3/1984	Bonhard et al.	260/112 B
4,473,494	9/1984	Tye	260/112 B
4,473,496	9/1984	Scannon	260/112 B
4,526,715	7/1985	Kothe et al.	260/112 B
4,529,719	7/1985	Tye	514/6
4,532,130	7/1985	Djordjevich et al.	424/101
4,584,130	4/1986	Bucci et al.	260/115
4,598,064	7/1986	Walder	514/6
4,600,531	7/1986	Walder	530/385
4,710,488	12/1987	Wong	514/6
4,730,936	3/1988	Thorjusen, Jr.	366/101
4,777,244	10/1988	Bonhard et al.	530/385
4,826,811	5/1989	Sehgal et al.	514/6
4,831,012	5/1989	Estep	514/6
4,857,636	8/1989	Hsia	530/385
4,861,867	8/1989	Estep	530/385
4,911,929	3/1990	Farmer et al.	424/450
4,987,154	1/1991	Long, Jr.	514/772
5,028,588	7/1991	Hoffman et al.	514/6
5,041,615	8/1991	Hai et al.	560/143
5,061,688	10/1991	Beissinger et al.	514/6
5,077,036	12/1991	Long, Jr.	424/5
5,080,885	1/1992	Long, Jr.	424/5
5,084,558	1/1992	Rausch et al.	530/385
5,114,932	5/1992	Runge	514/58
5,115,100	5/1992	Wu et al.	530/385
5,128,452	7/1992	Hai et al.	530/385
5,194,590	3/1993	Sehgal et al.	530/385
5,200,323	4/1993	Chang et al.	435/7.1
5,217,648	6/1993	Beissinger et al.	252/314
5,234,903	8/1993	Nho et al.	514/6
5,239,061	8/1993	Fronticelli et al.	530/385
5,250,665	10/1993	Kluger et al.	530/385
5,264,555	11/1993	Shorr et al.	530/385
5,281,579	1/1994	Estep	514/6
5,295,944	3/1994	Teicher et al.	600/1
5,296,465	3/1994	Rausch et al.	514/6
5,312,808	5/1994	Shorr et al.	514/6
5,334,705	8/1994	Bonaventura et al.	530/385
5,334,706	8/1994	Przybelski	530/385
5,344,393	9/1994	Roth et al.	604/4
5,349,054	9/1994	Bonaventura et al.	530/385
5,352,773	10/1994	Kandler et al.	530/385
5,386,014	1/1995	Nho et al.	530/385
5,407,428	4/1995	Segall et al.	604/28
5,438,041	8/1995	Zheng et al.	514/6
5,439,591	8/1995	Pliura et al.	210/635
5,449,759	9/1995	Hoffman et al.	530/385
5,451,205	9/1995	Roth et al.	604/6
5,464,814	11/1995	Sehgal et al.	514/6
5,478,805	12/1995	Shorr et al.	514/6
5,478,806	12/1995	Nho	514/6
5,480,866	1/1996	Bonaventura et al.	514/6
5,510,464	4/1996	Przybelski	530/385
5,525,630	6/1996	Hoffman	514/563

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

0 361 719 A1	4/1990	European Pat. Off. .
87/07832	12/1987	WIPO .
90/13309	11/1990	WIPO .
91/07190	5/1991	WIPO .

OTHER PUBLICATIONS

Mirhashemi et al., "Model analysis of the enhancement of tissue oxygenation by hemodilution due to increased microvascular flow velocity," *Microvasc. Res.* 34:290–301 (1987).

Mirhashemi et al., "Effects of hemodilution on skin microcirculation," *Am. J. Physiol.* 254:H411–H416 (1988).

Tsai and Intaglietta, "Local tissue oxygenation by statistically distributed sources," *Microvasc. Res.* 44:200–213 (1992).

(List continued on next page.)

Primary Examiner—Christopher S. F. Low
Assistant Examiner—Abdel A. Mohamed
Attorney, Agent, or Firm—Medlen & Carroll, LLP

[57] **ABSTRACT**

Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent.

35 Claims, 23 Drawing Sheets